Maverix Biomics has announced a strategic cooperation agreement with Elsevier. The agreement is to streamline the interpretation of raw next-generation sequencing (NGS) data to reveal new insights and to assist with critical decision making.

The Maverix Analytic Platform will complement Pathway Studio's sample-to-insight workflow and incorporation of biological data from Elsevier's biology journals.

The combination of the Maverix Analytic Platform and Elsevier's Pathway Studio is an integrated solution. It starts with raw NGS data and quickly produces genome alignment, quality metrics, variant and expression analysis, and the ability to analyse and visualise disease mechanisms derived from published scientific data.

"This collaboration gives more value to our customers, not only can they use the two great tools our companies produce, but they can now save time by seamlessly using them together. This reduces their workload, reduces complexity and increases accuracy of their analysis," said Ms Jaqui Hodgkinson, VP product development of Elsevier Life Sciences Solutions.

"We are pleased to be able to offer the Maverix Analytic Platform directly integrated with the Elsevier's Pathway Studio solution for researchers," said Mr Dave Mandelkern, Maverix president and co-founder. He added, "The combined offering will help researchers unravel hidden biology in experimental data or literature-based evidence, which will be especially useful in building and visualizing disease models."

Financial details of the deal were not disclosed.